[go: up one dir, main page]

DK3487505T3 - Indgivelse og dosering af diaminophenothiaziner - Google Patents

Indgivelse og dosering af diaminophenothiaziner Download PDF

Info

Publication number
DK3487505T3
DK3487505T3 DK17743330.7T DK17743330T DK3487505T3 DK 3487505 T3 DK3487505 T3 DK 3487505T3 DK 17743330 T DK17743330 T DK 17743330T DK 3487505 T3 DK3487505 T3 DK 3487505T3
Authority
DK
Denmark
Prior art keywords
diaminophenothiazines
dosage
administration
Prior art date
Application number
DK17743330.7T
Other languages
English (en)
Inventor
Claude Michel Wischik
Björn Olaf Schelter
Damon Jude Wischik
John Mervyn David Storey
Original Assignee
Wista Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59399428&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3487505(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1612863.9A external-priority patent/GB201612863D0/en
Priority claimed from GBGB1710382.1A external-priority patent/GB201710382D0/en
Application filed by Wista Lab Ltd filed Critical Wista Lab Ltd
Application granted granted Critical
Publication of DK3487505T3 publication Critical patent/DK3487505T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00Shaping or working of foodstuffs characterised by the products
    • A23P10/20Agglomerating; Granulating; Tabletting
    • A23P10/28Tabletting; Making food bars by compression of a dry powdered mixture
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00Shaping or working of foodstuffs characterised by the products
    • A23P10/30Encapsulation of particles, e.g. foodstuff additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D75/00Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
    • B65D75/28Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
    • B65D75/30Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
    • B65D75/32Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
    • B65D75/36Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet or blank being recessed and the other formed of relatively stiff flat sheet material, e.g. blister packages, the recess or recesses being preformed
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D2203/00Decoration means, markings, information elements, contents indicators
    • B65D2203/02Labels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Composite Materials (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
DK17743330.7T 2016-07-25 2017-07-25 Indgivelse og dosering af diaminophenothiaziner DK3487505T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1612863.9A GB201612863D0 (en) 2016-07-25 2016-07-25 Administration and dosage of diaminophenothiazines
GBGB1710382.1A GB201710382D0 (en) 2017-06-29 2017-06-29 Administration and dosage of Diaminophenothiazines
PCT/EP2017/068749 WO2018019823A1 (en) 2016-07-25 2017-07-25 Administration and dosage of diaminophenothiazines

Publications (1)

Publication Number Publication Date
DK3487505T3 true DK3487505T3 (da) 2023-05-30

Family

ID=59399428

Family Applications (2)

Application Number Title Priority Date Filing Date
DK17743330.7T DK3487505T3 (da) 2016-07-25 2017-07-25 Indgivelse og dosering af diaminophenothiaziner
DK23212899.1T DK4335517T3 (da) 2016-07-25 2017-07-25 Indgivelse og dosering af diaminofenothiaziner

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK23212899.1T DK4335517T3 (da) 2016-07-25 2017-07-25 Indgivelse og dosering af diaminofenothiaziner

Country Status (18)

Country Link
US (5) US11065256B2 (da)
EP (3) EP4335517B8 (da)
JP (1) JP7073330B2 (da)
KR (4) KR20230058533A (da)
CN (2) CN109789148A (da)
AU (3) AU2017301966B2 (da)
CA (1) CA3031578C (da)
DK (2) DK3487505T3 (da)
ES (2) ES2946165T3 (da)
FI (2) FI4335517T3 (da)
HR (2) HRP20230628T1 (da)
MX (2) MX385594B (da)
MY (2) MY210565A (da)
PL (1) PL3487505T3 (da)
PT (2) PT4335517T (da)
SG (1) SG11201900228YA (da)
SI (2) SI3487505T1 (da)
WO (1) WO2018019823A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007274057B2 (en) 2006-07-11 2012-12-13 TauRx Therapeutics Management Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
CN109789148A (zh) 2016-07-25 2019-05-21 维斯塔实验室有限公司 二氨基吩噻嗪的给药和剂量
ES2989458T3 (es) 2018-07-26 2024-11-26 Wista Lab Ltd Dosis optimizada de diaminofenotiazinas en poblaciones
AU2018440060B2 (en) 2018-09-05 2025-04-10 Genting Taurx Diagnostic Centre Sdn Bhd Network methods for neurodegenerative diseases
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909493D0 (en) * 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909506D0 (en) * 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
EP4146225B1 (en) * 2020-05-05 2024-10-09 WisTa Laboratories Ltd. Methylthioninium compounds for use in the treatment of hypoxemia
GB202006659D0 (en) * 2020-05-05 2020-06-17 Wista Lab Ltd Therapeutic treatments
AU2023279800A1 (en) 2022-05-31 2024-12-19 TauRx Therapeutics Management Ltd Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
WO2024061971A1 (en) 2022-09-21 2024-03-28 Wista Laboratories Ltd. Novel formulations and vehicles
WO2024184146A1 (en) 2023-03-03 2024-09-12 Wista Laboratories Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
WO2003101458A1 (en) 2002-05-31 2003-12-11 H. Lundbeck A/S A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
PT2322517T (pt) 2004-09-23 2019-07-30 Wista Lab Ltd Métodos de síntese química e purificação de compostos de diaminofenotiazínio incluindo cloreto de metiltionínio (mtc)
MY172157A (en) 2006-03-29 2019-11-15 Wista Lab Ltd Thioninium compounds and their use
KR100983301B1 (ko) 2006-03-29 2010-09-20 위스타 레보레이토리스 리미티드 3,7―다이아미노―10h―페노티아진염 및 이의 용도
PL2004155T3 (pl) * 2006-03-29 2018-08-31 Wista Laboratories Ltd. Inhibitory agregacji białek
AU2007274057B2 (en) 2006-07-11 2012-12-13 TauRx Therapeutics Management Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
FR2903696B1 (fr) 2006-07-12 2011-02-11 Provence Technologies Procede de purification de composes diaminophenothiazium
PL2167095T3 (pl) * 2007-06-19 2019-11-29 Wista Lab Ltd Związki fenotiazynowe do leczenia łagodnych zaburzeń poznawczych
EP2954932B1 (en) 2007-10-03 2018-09-19 WisTa Laboratories Ltd. Therapeutic use of diaminophenothiazines
WO2009060191A2 (en) 2007-11-05 2009-05-14 Wista Laboratories Ltd. Systems for clinical trials
WO2010078659A1 (en) 2009-01-12 2010-07-15 Foster Health Inc. Compositions and methods for nutritional prevention and treatment of alzheimer's-associated conditions
WO2010104375A1 (en) 2009-03-12 2010-09-16 N.V. Nutricia Stigmasterol for the treatment of alzheimer's disease
MX2012003035A (es) 2009-09-24 2012-06-12 Wista Lab Ltd Proceso.
BR112012006638B1 (pt) 2009-09-24 2020-05-26 Wista Laboratories Ltd. Forma c de di-hidrato de cloreto de metiltionínio, seu processo de preparação, e composição farmacêutica
DE102010062810B4 (de) 2010-09-07 2014-03-13 Immungenetics Ag 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien
SG10201602111VA (en) 2010-11-30 2016-04-28 Wista Lab Ltd Formulations Comprising Methylthioninium Chloride
JP5898701B2 (ja) * 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
CN109789148A (zh) * 2016-07-25 2019-05-21 维斯塔实验室有限公司 二氨基吩噻嗪的给药和剂量
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
ES2989458T3 (es) 2018-07-26 2024-11-26 Wista Lab Ltd Dosis optimizada de diaminofenotiazinas en poblaciones
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions

Also Published As

Publication number Publication date
KR102592614B1 (ko) 2023-10-24
PT3487505T (pt) 2023-06-07
AU2023203084B2 (en) 2025-03-06
HRP20251365T1 (hr) 2025-12-19
JP2019527216A (ja) 2019-09-26
EP4335517B1 (en) 2025-08-27
SI3487505T1 (sl) 2023-10-30
MX2019000946A (es) 2019-05-13
EP4335517A3 (en) 2024-08-07
MX2021009899A (es) 2021-09-14
MX385594B (es) 2025-03-18
MY210565A (en) 2025-09-30
US20230346794A1 (en) 2023-11-02
PT4335517T (pt) 2025-10-07
US11759469B2 (en) 2023-09-19
US20250262219A1 (en) 2025-08-21
US11065256B2 (en) 2021-07-20
DK4335517T3 (da) 2025-09-29
PL3487505T3 (pl) 2023-10-09
JP7073330B2 (ja) 2022-05-23
FI4335517T3 (fi) 2025-10-21
US20230165877A1 (en) 2023-06-01
CA3031578A1 (en) 2018-02-01
KR20230058533A (ko) 2023-05-03
EP3487505B1 (en) 2023-05-03
FI3487505T3 (fi) 2023-06-05
ES3046673T3 (en) 2025-12-02
US12310973B2 (en) 2025-05-27
AU2022291420A1 (en) 2023-02-02
KR20190031552A (ko) 2019-03-26
MY201804A (en) 2024-03-19
WO2018019823A1 (en) 2018-02-01
KR20230003261A (ko) 2023-01-05
AU2022291420B2 (en) 2024-05-09
AU2017301966A1 (en) 2019-03-07
WO2018019823A8 (en) 2018-04-05
AU2017301966B2 (en) 2022-09-22
ES2946165T3 (es) 2023-07-13
KR20240074909A (ko) 2024-05-28
CN116531386A (zh) 2023-08-04
US20220008431A1 (en) 2022-01-13
EP3487505A1 (en) 2019-05-29
KR102475825B1 (ko) 2022-12-08
HRP20230628T1 (hr) 2023-09-29
EP4223297A3 (en) 2023-11-15
EP4223297A2 (en) 2023-08-09
SI4335517T1 (sl) 2025-11-28
SG11201900228YA (en) 2019-02-27
EP4335517A2 (en) 2024-03-13
EP4335517B8 (en) 2025-10-22
US20200016165A1 (en) 2020-01-16
US12128051B2 (en) 2024-10-29
AU2023203084A1 (en) 2023-06-08
CA3031578C (en) 2025-07-08
CN109789148A (zh) 2019-05-21

Similar Documents

Publication Publication Date Title
DK4335517T3 (da) Indgivelse og dosering af diaminofenothiaziner
DK3506884T4 (da) Sammensætninger til indgivelse af medicin og anvendelser deraf
DK3212230T3 (da) Dosering og indgivelse af ikke-fucosylerede anti-CD40-antistoffer
DK3278803T3 (da) Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor
DK3244948T3 (da) Bestemmelse af medikamentdosis
DK3302565T3 (da) Faste doseringsformer af palbociclib
DK3703784T3 (da) Anordning til indgivelse af lægemidler
DK3302638T3 (da) Anordning til indgivelse af lægemidler
EP3352757C0 (en) ADMINISTRATION OF DEUTERIUM-MODIFIED CFTR POTENTIATION AGENTS
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3354282T3 (da) Glycan-terapeutiske midler og relaterede fremgangsmåder deraf
DK3988117T3 (da) Terapeutiske antistoffer og deres anvendelser
DK3285831T3 (da) Underenhed af en medikamenttilførselsanordning og en medikamenttilførselsanordning
PL3362084T3 (pl) Urządzenia do podawania dojelitowego i powiązane sposoby zastosowania
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3514153T3 (da) Pyrimidinforbindelse og farmaceutisk anvendelse deraf
DK3113782T3 (da) Lægemiddelleveringssystemer og fremgangsmåder til behandling af blærekræft med gemcitabin
DK3265126T3 (da) Kombinationsformulering af tesofensin og metoprolol
DK3319609T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antibakterielle lægemiddelkombinationer
DK3380525T3 (da) Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
DK3297651T3 (da) Synergistisk kombination af neuronale levedygtighedsfaktorer og anvendelser deraf
EP3526186A4 (en) SUBSTITUTED HYDROXY STYLENE AND THEIR THERAPEUTIC APPLICATIONS
DK3275453T3 (da) Farmaceutisk sammensætning med silibinin og ve
DK3388085T3 (da) Farmaceutisk sammensætning og anvendelser deraf